Retroperitoneal Lymph Node Dissection in Testicular Cancer

Surgical Oncology Clinics of North America

Volumn 16, Issue 1, 2007, Pages 199-220

  Jacobsen, Niels Erik B ^a   Foster, Richard S ^a   Donohue, John P ^a  

^a INDIANA UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; CISPLATIN; ETOPOSIDE;

ADVANCED CANCER; CANCER DIAGNOSIS; CANCER STAGING; COMBINATION CHEMOTHERAPY; GERM CELL TUMOR; HUMAN; LUNG TOXICITY; LYMPH NODE DISSECTION; MALE; MULTIPLE CYCLE TREATMENT; ORCHIECTOMY; PARAAORTIC LYMPH NODE; PREOPERATIVE CARE; REVIEW; SURGICAL APPROACH; SURGICAL TECHNIQUE; TESTIS CANCER;

ALPHA-FETOPROTEINS; EJACULATION; HUMANS; LYMPH NODE EXCISION; MALE; NEOPLASM METASTASIS; NEOPLASM STAGING; NEOPLASMS, GERM CELL AND EMBRYONAL; ORCHIECTOMY; POSTOPERATIVE CARE; RETROPERITONEAL SPACE; TESTICULAR NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 33847296297     PISSN: 10553207     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.soc.2006.10.003     Document Type: Review

References (78)

1. Jemal A., Siegel R., Ward E., et al. Cancer statistics, 2006. CA Cancer J Clin 56 2 (2006) 106-130
2. Coogan C.L., Foster R.S., Simmons G.R., et al. Bilateral testicular tumors: management and outcome in 21 patients. Cancer 83 3 (1998) 547-552
3. Albers P., Albrecth W., Algaba F., et al. Guidelines on testicular cancer. Eur Urol 48 6 (2005) 885-894
4. Reuter V.E. Anatomy and pathology of testis cancer. In: Vogelzang N.J., Scardino P.T., and Shipley W.U. (Eds). Comprehensive textbook of genitourinary oncology. 3rd edition (2006), Lippincott Williams and Wilkins, Philadelphia 573-585
5. American Joint Committee on Cancer: AJCC cancer staging manual. 6th edition (2002), Springer, New York
6. International Germ Cell Cancer Collaborative Group. International germ cell consensus classification: a prognostic factor-based staging system for metastatic germ cell cancers. J Clin Oncol 15 2 (1997) 594-603
7. Whitmore Jr. W.F. Surgical treatment of clinical stage I nonseminomatous germ cell tumors of the testis. Cancer Treat Rep 66 1 (1982) 5-10
8. Hilton S., Herr H.W., Teitcher J.B., et al. CT detection of retroperitoneal lymph node metastases in patients with clinical stage I testicular nonseminomatous germ cell cancer: assessment of size and distribution criteria. AJR Am J Roentgenol 169 2 (1997) 521-525
9. Leibovitch L., Foster R.S., Kopecky K.K., et al. Improved accuracy of computerized tomography based clinical staging in low stage nonseminomatous germ cell cancer using size criteria of retroperitoneal lymph nodes. J Urol 154 5 (1995) 1759-1763
10. Carlsson-Farrelly E., Boquist L., and Ljungberg B. Accuracy of clinical staging in non-seminomatous testicular cancer a single centre experience of retroperitoneal lymph node dissection. Scand J Urol Nephrol 29 4 (1995) 501-506
11. Fernandez E.B., Moul J.W., Foley J.P., et al. Retroperitoneal imaging with third and fourth generation computed axial tomography in clinical stage I nonseminomatous germ cell tumors. Urology 44 4 (1994) 548-552
12. Stephenson A.J., Bosl G.J., Motzer R.J., et al. Retroperitoneal lymph node dissection for nonseminomatous germ cell testicular cancer: impact of patient selection factors on outcome. J Clin Oncol 23 12 (2005) 2781-2788
13. Albers P., Siener R., Kliesch S., et al. Risk factors for relapse in clinical stage I nonseminomatous testicular germ cell tumors: results of the German Testicular Cancer Study Group Trial. J Clin Oncol 21 8 (2003) 1505-1512
14. Donohue J.P., Thornhill J.A., Foster R.S., et al. Retroperitoneal lymphadenectomy for clinical stage A testis cancer (1965 to 1989): modifications of technique and impact on ejaculation. J Urol 149 2 (1993) 237-243
15. Klepp O., Olsson A.M., Henrikson H., et al. Prognostic factors in clinical stage I nonseminomatous germ cell tumors of the testis: multivariate analysis of a prospective multicenter study. J Clin Oncol 8 3 (1990) 509-518
16. Sturgeon J.F., Jewett M.A., Alison R.E., et al. Surveillance after orchidectomy for patients with clinical stage I nonseminomatous testis tumors. J Clin Oncol 10 4 (1992) 564-568
17. Sogani P.C., Perrotti M., Herr H.W., et al. Clinical stage I testis cancer: long-term outcome of patients on surveillance. J Urol 159 3 (1998) 855-858
18. Donohue J.P., Thornhill J.A., Foster R.S., et al. Clinical stage B non-seminomatous germ cell testis cancer: the Indiana University experience (1965-1989) using routine primary retroperitoneal lymph node dissection. Eur J Cancer 31A 10 (1995) 1599-1604
19. Donohue J.P., Thornhill J.A., Foster R.S., et al. Primary retroperitoneal lymph node dissection in clinical stage A non-seminomatous germ cell testis cancer. Review of the Indiana University experience 1965-1989. Br J Urol 71 3 (1993) 326-335
20. Richie J.P., and Kantoff P.W. Is adjuvant chemotherapy necessary for patients with stage B1 testicular cancer?. J Clin Oncol 9 8 (1991) 1393-1396
21. SD Williams, DM Stablein, LH Einhorn, et al. Immediate adjuvant chemotherapy versus observation with treatment at relapse in pathological stage II testicular cancer. N Engl J Med 1987;317(23):1433-8.
22. Kondagunta G.V., Sheinfeld J., Mazumdar M., et al. Relapse-free and overall survival in patients with pathologic stage II nonseminomatous germ cell cancer treated with etoposide and cisplatin adjuvant chemotherapy. J Clin Oncol 22 3 (2004) 464-467
23. Pohar K., Rabbani F., Bosl G., et al. Results of retroperitoneal lymph node dissection for clinical stage I and II pure embryonal carcinoma of the testis. J Urol 170 4 (2003) 1155-1158
24. Dieckmann K.P., Albers P., Classen J., et al. Late relapse of testicular germ cell neoplasms: a descriptive analysis of 122 cases. J Urol 173 3 (2005) 824-829
25. Michael H., Lucia J., Foster R.S., et al. The pathology of late recurrence of testicular germ cell tumors. Am J Surg Pathol 24 2 (2000) 257-273
26. Motzer R.J., Amsterdam A., Prieto V., et al. Teratoma with malignant transformation: diverse malignant histologies arising in men with germ cell tumors. J Urol 159 1 (1998) 133-138
27. Comiter C.V., Kibel A.S., Richie J.P., et al. Prognostic features of teratomas with malignant transformation: a clinicopathological study of 21 cases. J Urol 159 3 (1998) 859-863
28. Donadio A.C., Motzer R.J., Bajorin D.F., et al. Chemotherapy for teratoma with malignant transformation. J Clin Oncol 21 23 (2003) 4285-4291
29. Studer U.E., Fey M.F., Calderoni A., et al. Adjuvant chemotherapy after orchiectomy in high-risk patients with clinical stage I non-seminomatous testicular cancer. Eur Urol 23 4 (1993) 444-449
30. Bohlen D., Borner M., Sonntag R.W., et al. Long-term results following adjuvant chemotherapy in patients with clinical stage I testicular nonseminomatous malignant germ cell tumors with high risk factors. J Urol 161 4 (1999) 1148-1152
31. Cullen M.H., Stenning S.P., Parkinson M.C., et al. Short-course adjuvant chemotherapy in high-risk stage I nonseminomatous germ cell tumors of the testis: a Medical Research Council report. J Clin Oncol 14 4 (1996) 1106-1113
32. Baniel J., Foster R.S., Einhorn L.H., et al. Late relapse of clinical stage I testicular cancer. J Urol 154 4 (1995) 1370-1372
33. Pont J., Albrecht W., Postner G., et al. Adjuvant chemotherapy for high-risk clinical stage I nonseminomatous testicular germ cell cancer: long-term results of a prospective trial. J Clin Oncol 14 2 (1996) 441-448
34. Oliver R.T., Raja M.A., Ong J., et al. Pilot study to evaluate impact of a policy of adjuvant chemotherapy for high risk stage 1 malignant teratoma on overall relapse rate of stage 1 cancer patients. J Urol 148 5 (1992) 1453-1455
35. Baniel J., Foster R.S., Rowland R.G., et al. Complications of primary retroperitoneal lymph node dissection. J Urol 152 2 (1994) 424-427
36. Beck S.D.W., Peterson M.D., Foster R.S., et al. What is the short-term morbidity of primary retroperitoneal lymph node dissection in a contemporary group of patients?. J Urol 175 4S (2006) A586
37. Bajorin D.F., Motzer R.J., Rodriguez E., et al. Acute nonlymphocytic leukemia in germ cell tumor patients treated with etoposide-containing chemotherapy. J Natl Cancer Inst 85 1 (1993) 60-62
38. Huddart R.A., Normal A., Shahidi M., et al. Cardiovascular disease as a long-term complication of treatment for testicular cancer. J Clin Oncol 21 8 (2003) 1513-1523
39. Einhorn L.H., Williams S.D., Loehrer P.J., et al. Evaluation of optimal duration of chemotherapy in favourable-prognosis disseminated germ cell tumors: a southeastern cancer study group protocol. J Clin Oncol 7 3 (1989) 387-391
40. de Wit R., Stoter G., Kaye S.B., et al. Importance of bleomycin in combination chemotherapy for good-prognosis testicular nonseminoma: a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group. J Clin Oncol 15 5 (1997) 1837-1843
41. Debono D.J., Heilman D.K., Einhorn L.H., et al. Decision analysis for avoiding postchemotherapy surgery in patients with disseminated nonseminomatous germ cell tumors. J Clin Oncol 15 4 (1997) 1455-1464
42. Steyerberg E.W., Keizer H.J., Fossa S.D., et al. Prediction of residual retroperitoneal mass histology after chemotherapy for metastatic nonseminomatous germ cell tumor: multivariate analysis of individual patient data from six study groups. J Clin Oncol 13 5 (1995) 1177-1187
43. Baniel J., Foster R.S., Gonin R., et al. Late relapse of testicular cancer. J Clin Oncol 13 5 (1995) 1170-1176
44. Shahidi M., Norman A.R., Dearnaley D.P., et al. Late recurrence in 1263 men with testicular germ cell tumors. Multivariate analysis of risk factors and implications for management. Cancer 95 3 (2002) 520-530
45. Beck S.D., Foster R.S., Bihrle R., et al. Teratoma in the orchiectomy specimen and volume of metastases are predictors of retroperitoneal teratoma in post-chemotherapy nonseminomatous testis cancer. J Urol 168 4 (2002) 1402-1404
46. Vergouwe Y., Steyerberg E.W., de Wit R., et al. External validity of a prediction rule for residual mass histology in testicular cancer: an evaluation for good prognosis patients. Br J Cancer 88 6 (2003) 843-847
47. Donohue J.P., and Foster R.S. Management of retroperitoneal recurrences. Seminoma and nonseminoma. Urol Clin North Am 21 4 (1994) 761-772
48. Loehrer Sr. P.J., Hui S., Clark S., et al. Teratoma following cisplatin-based combination chemotherapy for nonseminomatous germ cell tumors: a clinicopathological correlation. J Urol 135 6 (1986) 1183-1189
49. Tait D., Peckham M.J., Hendry W.F., et al. Post-chemotherapy surgery in advanced non-seminomatous germ-cell testicular tumours: the significance of histology with particular reference to differentiated (mature) teratoma. Br J Cancer 50 5 (1984) 601-609
50. Stenning S.P., Parkinson M.C., Fisher C., et al. Postchemotherapy residual masses in germ cell tumor patients: content, clinical features, and prognosis. Medical Research Council Testicular Tumour Working Party. Cancer 83 7 (1998) 1409-1419
51. Fox E.P., Weathers T.D., Williams S.D., et al. Outcome analysis for patients with persistent nonteratomatous germ cell tumor in postchemotherapy retroperitoneal lymph node dissections. J Clin Oncol 11 7 (1993) 1294-1299
52. Fizazi K., Tjulandin S., Salvioni R., et al. Viable malignant cells after primary chemotherapy for disseminated nonseminomatous germ cell tumors: prognostic factors and role of postsurgery chemotherapy results from an international study group. J Clin Oncol 19 10 (2001) 2647-2657
53. Einhorn L.H. Testicular cancer as a model for a curable neoplasm: The Richard and Hinda Rosenthal Foundation Award Lecture. Cancer Res 41 91 (1981) 3275-3280
54. Mosharafa A.A., Foster R.S., Leibovich B.C., et al. Is post-chemotherapy resection of seminomatous elements associated with higher acute morbidity?. J Urol 169 6 (2003) 2126-2128
55. Herr H.W., Sheinfeld J., Puc H.S., et al. Surgery for a post-chemotherapy residual mass in seminoma. J Urol 157 3 (1997) 860-862
56. Puc H.S., Heelan R., Mazumdar M., et al. Management of residual mass in advanced seminoma: results and recommendations from the Memorial Sloan-Kettering Cancer Center. J Clin Oncol 14 2 (1996) 454-460
57. 18fluoro-deoxy-D-glucose positron emission tomography is a reliable predictor for viable tumor in postchemotherapy seminoma: an update of the prospective multicentric SEMPET trial. J Clin Oncol 22 6 (2004) 1034-1039
58. Baniel J., Foster R.S., Rowland R.G., et al. Complications of post-chemotherapy retroperitoneal lymph node dissection. J Urol 153 3 (1995) 976-980
59. Baniel J., and Sella A. Complications of retroperitoneal lymph node dissection in testicular cancer: primary and post-chemotherapy. Semin Surg Oncol 17 4 (1999) 263-267
60. Hay J., Shahzeidi S., and Laurent G. Mechanisms of bleomycin-induced lung damage. Arch Toxicol 65 2 (1991) 81-94
61. Donat S.M., and Levy D.A. Bleomycin associated pulmonary toxicity: is perioperative oxygen restriction necessary?. J Urol 160 4 (1998) 1347-1352
62. Goldiner P.L., Carlon G.C., Cvitkovic E., et al. Factors influencing postoperative morbidity and mortality in patients treated with bleomycin. Br Med J 1 6128 (1978) 1664-1667
63. Zwikler M.P., Iancu D., and Michel R.P. Effects of pulmonary fibrosis on the distribution of edema. Morphometric analysis. Am J Respir Crit Care Med 149 5 (1994) 1276-1285
64. Mosharafa A.A., Foster R.S., Koch M.O., et al. Complications of post-chemotherapy retroperitoneal lymph node dissection for testis cancer. J Urol 171 5 (2004) 1839-1841
65. Coogan C.L., Hejase M.J., Wahle G.R., et al. Nerve sparing post-chemotherapy retroperitoneal lymph node dissection for advanced testicular cancer. J Urol 156 5 (1996) 1656-1658
66. Donohue J.P. Retroperitoneal lymphadenectomy: the anterior approach including bilateral suprarenal hilar dissection. Urol Clin North Am 4 3 (1977) 509-521
67. Donohue J.P., Zachary J.M., and Maynard B.R. Distribution of nodal metastases in nonseminomatous testis cancer. J Urol 128 2 (1982) 315-320
68. Ray B., Hajdu S.I., and Whitmore Jr. W.F. Distribution of retroperitoneal lymph node metastases in testicular germinal tumors. Cancer 33 2 (1974) 340-348
69. Weissbach L., and Boedefeld E. Localization of solitary and multiple metastases in stage II non seminomatous testis tumors as a basis for a modified staging lymph node dissection in stage I. J Urol 138 1 (1982) 77-82
70. Schmeller N.T., Siegelman S.S., and Walsh P.C. Anatomical considerations in suprahilar lymph node dissection for testicular tumors. Urol Int 36 6 (1981) 341-345
71. Donohue J.P., and Foster R.S. Retroperitoneal lymphadenectomy in staging and treatment: the development of nerve-sparing techniques. Urol Clin North Am 25 3 (1998) 461-468
72. Narayan P., Lang P.H., and Fraley E.E. Ejaculation and fertility after extended retroperitoneal lymph node dissection for testicular cancer. World J Urol 127 4 (1982) 685-688
73. Donohue J.P., and Rowland R.G. Complications of retroperitoneal lymph node dissection. J Urol 125 3 (1981) 338-340
74. Donohue J.P., Foster R.S., Rowland R.G., et al. Nerve-sparing retroperitoneal lymphadenectomy with preservation of ejaculation. J Urol 144 2 (1990) 287-292
75. Jewett M.A., Kong Y.S., Goldberg S.D., et al. Retroperitoneal lymphadenectomy for testis tumor with nerve sparing for ejaculation. J Urol 139 6 (1988) 1220-1224
76. Richie J.P., Socinsky M.A., Fung C.Y., et al. Management of patients with clinical stage I or II nonseminomatous germ cell tumors of the testis. Evolving therapeutic options. Arch Surg 122 12 (1987) 1443-1445
77. Beck S.D.W., Foster R.S., Bihrle R., et al. Is full bilateral retroperitoneal lymph node dissection (RPLND) always necessary for post chemotherapy residual tumor?. [abstract A430]. J Urol 173 4 (2005) 117
78. Baniel J., Foster R.S., Rowland R.G., et al. Management of chylous ascites after retroperitoneal lymph node dissection for testicular cancer. J Urol 150 5 (1993) 1422-1424